We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+3.48%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$942M
AUM Growth
+$47.5M
(+5.3%)
Cap. Flow
+$57.7M
Cap. Flow
% of AUM
6.13%
Top 10 Holdings %
Top 10 Hldgs %
36.92%
Holding
174
New
107
Increased
33
Reduced
23
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$22.8M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$16.4M |
| 3 |
Collegium Pharmaceutical
COLL
|
+$15.5M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$13.7M |
| 5 |
AERI
Aerie Pharmaceuticals
AERI
|
+$10.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$24.4M |
| 2 |
Molina Healthcare
MOH
|
+$17.5M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$14.2M |
| 4 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$13.9M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$11.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.63% |
| 2 | Industrials | 0.89% |
| 3 | Technology | 0.84% |
| 4 | Financials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Cardinal Health
CAH
$53.7B
| $333K | 0.04% |
+6,171
| New | +$316K |
|
|
ARNA
102
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $332K | 0.04% |
+7,208
| New | +$292K |
|
|
BPMC
103
DELISTED
Blueprint Medicines
BPMC
| $327K | 0.03% |
+4,184
| New | +$291K |
|
104
Humana
HUM
$43.9B
| $321K | 0.03% |
+949
| New | +$308K |
|
105
Rigel Pharmaceuticals
RIGL
$723M
| $317K | 0.03% |
+9,861
| New | +$296K |
|
|
STML
106
DELISTED
Stemline Therapeutics, Inc.
STML
| $308K | 0.03% |
+18,538
| New | +$297K |
|
107
Centene
CNC
$30.5B
| $303K | 0.03% |
+4,180
| New | +$290K |
|
|
XENT
108
DELISTED
Intersect ENT, Inc
XENT
| $294K | 0.03% |
+10,226
| New | +$307K |
|
109
GSK
GSK
$107B
| $293K | 0.03% |
+5,840
| New | +$297K |
|
110
Travere Therapeutics
TVTX
$5.17B
| $288K | 0.03% |
+10,036
| New | +$287K |
|
|
MDCO
111
DELISTED
Medicines Co
MDCO
| $288K | 0.03% |
+9,614
| New | +$362K |
|
112
Ironwood Pharmaceuticals
IRWD
$586M
| $284K | 0.03% |
+18,388
| New | +$291K |
|
113
Talphera
TLPH
$68M
| $284K | 0.03% |
+3,689
| New | +$237K |
|
114
AstraZeneca
AZN
$269B
| $281K | 0.03% |
+3,550
| New | +$269K |
|
|
RVNC
115
DELISTED
Revance Therapeutics, Inc.
RVNC
| $279K | 0.03% |
+11,234
| New | +$306K |
|
116
Zimmer Biomet
ZBH
$18.8B
| $276K | 0.03% |
+2,162
| New | +$257K |
|
117
Steris
STE
$22.9B
| $275K | 0.03% |
+2,406
| New | +$272K |
|
118
Icon
ICLR
$13.7B
| $274K | 0.03% |
+1,780
| New | +$255K |
|
119
Regenxbio
RGNX
$616M
| $267K | 0.03% |
+3,533
| New | +$255K |
|
|
MYOK
120
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $264K | 0.03% |
+4,051
| New | +$238K |
|
121
Theravance Biopharma
TBPH
$873M
| $260K | 0.03% |
+7,945
| New | +$217K |
|
122
Baxter International
BAX
$12.8B
| $254K | 0.03% |
+3,298
| New | +$245K |
|
|
SYNH
123
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $250K | 0.03% |
+4,841
| New | +$237K |
|
|
WBA
124
DELISTED
Walgreens Boots Alliance
WBA
| $249K | 0.03% |
+3,418
| New | +$232K |
|
|
SHPG
125
DELISTED
Shire pic
SHPG
| $236K | 0.03% |
1,300
-3,200
| -71% | -$554K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q3 2018 Portfolio in Review
As of Q3 2018, Sectoral Asset Management held 174 positions worth $942M, up 5.3% from $894M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Sectoral Asset Management deployed $57.7M of net new capital in Q3 2018, opening 107 new positions and adding to 33 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 76,846 shares worth $14.8M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $24.4M trimmed.
- Sectoral Asset Management's largest Q3 2018 buy was Vertex Pharmaceuticals: 76,846 shares worth $14.8M.
- Sectoral Asset Management added most to Celgene Corp in Q3 2018, an estimated $22.8M increase.
- Sectoral Asset Management's biggest Q3 2018 reduction was Sarepta Therapeutics, cutting an estimated $24.4M.
- Sectoral Asset Management fully exited Molina Healthcare in Q3 2018, selling an estimated $17.5M.
- Sectoral Asset Management's ten largest holdings make up 37% of its $942M portfolio in Q3 2018.
- Sectoral Asset Management opened 107 new positions and closed 6 in Q3 2018.
- Sectoral Asset Management's portfolio value rose 5.3% quarter-over-quarter to $942M.
Based on Sectoral Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.